https://lirametostatinhibitor.....com/long-term-specia
The HER2-low model has introduced a challenge to the conventional interpretation of HER2 overexpression, and subsequently, a need for more sophisticated HER2 testing, which better accounts for the intratumoral heterogeneity and spatial distribution of the HER2 protein. The possibility of low HER2 continuing to function as a mere indicator of HER2-positive tumors suitable for antibody-drug conjugate treat
Synes godt om
Kommentar
Del
